Advertisement

Drug Safety

, Volume 42, Issue 11, pp 1355–1363 | Cite as

Non-Vitamin K Antagonist Oral Anticoagulants and Angioedema: A Cohort and Case-Crossover Study

  • John G. ConnollyEmail author
  • Sebastian Schneeweiss
  • Robert J. Glynn
  • Joshua J. Gagne
Original Research Article
  • 163 Downloads

Abstract

Introduction

Patients taking non-vitamin K antagonist oral anticoagulants (NOACs) such as dabigatran, rivaroxaban, and apixaban have reported experiencing angioedema in randomized trials and routine care.

Objective

The aim of this study was to quantify the association between NOACs and angioedema relative to warfarin among routinely treated patients with atrial fibrillation in a cohort study. We also compared warfarin users with non-users in a case-crossover study.

Methods

We utilized a cohort design that drew eligible patients from the Truven Health MarketScan Commercial database, the Optum© Clinformatics® Data Mart, and Medicare. Within each database, we compared the 6-month relative rate of angioedema among new users of NOACs (dabigatran, rivaroxaban, apixaban) and new users of warfarin. We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) after adjusting for confounders using propensity score stratification, and meta-analyzed the database-specific HRs using a random-effects model. We also estimated an odds ratio (OR) for the association between warfarin and angioedema using a case-crossover design, a self-controlled design that controls for time-invariant confounders.

Results

In the cohort study, we observed 249 incident angioedema events among 267,681 NOAC initiators and 281,143 warfarin initiators across all databases. The meta-analyzed HR for angioedema comparing any NOAC versus warfarin was 0.98 (95% CI 0.76–1.27). In the case-crossover design, the OR for the association between warfarin and angioedema was 0.91 (95% CI 0.68–1.21) based on 431 cases.

Conclusions

Our estimates were inconsistent with substantial short-term relative increases in the rate of angioedema associated with oral anticoagulant therapy.

Notes

Acknowledgments

John G. Connolly received a training grant from the Pharmacoepidemiology Program at the Harvard T.H. Chan School of Public Health, which is partially supported by training grants from Pfizer, Takeda, Bayer, and Asisa. This project was internally funded by the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital.

Compliance with Ethical Standards

Conflicts of Interest

John G. Connolly has no conflicts of interest to declare. Sebastian Schneeweiss is a consultant to WHISCON LLC and Aetion Inc., a software manufacturer in which he also owns equity. He is principal investigator of investigator-initiated grants to the Brigham and Women’s Hospital from Genentech, Bayer, Boehringer Ingelheim, US FDA, and the Patient-Centered Outcomes Research Institute, not directly related to the topic of this submitted work. Robert J. Glynn reports grants from Pfizer, Novartis, and Kowa outside the submitted work. Joshua J. Gagne has received salary support from grants from Novartis Pharmaceutical Corporation and Eli Lilly and Company to Brigham and Women’s Hospital, and is a consultant to Aetion, Inc. and Optum Inc., all for unrelated work.

Funding

This work was funded internally by the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital.

Supplementary material

40264_2019_852_MOESM1_ESM.docx (559 kb)
Supplementary material 1 (DOCX 559 kb)

References

  1. 1.
    Desai NR, Krumme AA, Schneeweiss S, Shrank WH, Brill G, Pezalla EJ, et al. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications. Am J Med. 2014;127(1075–1082):e1.Google Scholar
  2. 2.
    da Silva RMFL. Novel oral anticoagulants in non-valvular atrial fibrillation. Cardiovasc Hematol Agents Med Chem. 2014;12:3–8.CrossRefGoogle Scholar
  3. 3.
    Moellman JJ, Bernstein JA, Lindsell C, Banerji A, Busse PJ, Camargo CA, et al. A consensus parameter for the evaluation and management of angioedema in the emergency department. Acad Emerg Med. 2014;21:469–84.CrossRefGoogle Scholar
  4. 4.
    Boehringer Ingelheim. Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate. ClinicalTrials.gov [cited 16 Aug 2018]. https://clinicaltrials.gov/ct2/show/NCT00262600.
  5. 5.
    Johnson & Johnson Pharmaceutical Research & Development, LLC. An Efficacy and safety study of rivaroxaban with warfarin for the prevention of stroke and non-central nervous system systemic embolism in patients with non-valvular atrial fibrillation. ClinicalTrials.gov [cited 16 Aug 2018]. https://clinicaltrials.gov/ct2/show/NCT00403767.
  6. 6.
    Bristol-Myers Squibb. Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation. ClinicalTrials.gov [cited 16 Aug 2018]. https://clinicaltrials.gov/ct2/show/NCT00412984.
  7. 7.
    Highlights of Prescribing Information for Pradaxa [cited 27 Jun 2019]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022512s035lbl.pdf.
  8. 8.
    Highlights of Prescribing Information for Xarelto [cited 27 Jun 2019]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022406s030s032lbledt.pdf.
  9. 9.
    FDA Adverse Event Reporting System (FAERS) Public Dashboard. FDA. 2018 [cited 28 Jun 2019]. http://www.fda.gov/drugs/fda-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard.
  10. 10.
    Altin C, Ozturkeri OAY, Gezmis E, Askin U. Angioedema due to the new oral anticoagulant rivaroxaban. Ann Card Anaesth. 2014;17:173–4.CrossRefGoogle Scholar
  11. 11.
    Banaga Y, Mohmmed K, Mustafa H, Barrett J. Angioedema 2 months after administration of rivaroxaban (Xarelto). J Clin Case Rep. 2017;7(12):1059.CrossRefGoogle Scholar
  12. 12.
    Nissen T, Wynn R. The clinical case report: a review of its merits and limitations. BMC Res Notes. 2014;7:264.CrossRefGoogle Scholar
  13. 13.
    Schneider G, Kachroo S, Jones N, Crean S, Rotella P, Avetisyan R, et al. A systematic review of validated methods for identifying anaphylaxis, including anaphylactic shock and angioneurotic edema, using administrative and claims data. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):240–7.CrossRefGoogle Scholar
  14. 14.
    Connolly JG, Schneeweiss S, Glynn RJ, Gagne JJ. Quantifying bias reduction with fixed-duration versus all-available covariate assessment periods. Pharmacoepidemiol Drug Saf. 2019;28(5):665–70.CrossRefGoogle Scholar
  15. 15.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefGoogle Scholar
  16. 16.
    Stürmer T, Rothman KJ, Avorn J, Glynn RJ. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution—a simulation study. Am J Epidemiol. 2010;172:843–54.CrossRefGoogle Scholar
  17. 17.
    Toh S, Reichman ME, Houstoun M, Ross Southworth M, Ding X, Hernandez AF, et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med. 2012;172:1582–9.CrossRefGoogle Scholar
  18. 18.
    Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension. 2008;51(6):1624–30.CrossRefGoogle Scholar
  19. 19.
    Yoshida K, Solomon DH, Kim SC. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol. 2015;11:437–41.CrossRefGoogle Scholar
  20. 20.
    Schneeweiss S, Patrick AR, Stürmer T, Brookhart MA, Avorn J, Maclure M, et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care. 2007;45:S131–42.CrossRefGoogle Scholar
  21. 21.
    Gagne JJ, Fireman B, Ryan PB, Maclure M, Gerhard T, Toh S, et al. Design considerations in an active medical product safety monitoring system. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):32–40.CrossRefGoogle Scholar
  22. 22.
    Maclure M, Mittleman MA. Should we use a case-crossover design? Annu Rev Public Health. 2000;21:193–221.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Pharmacoepidemiology and Pharmacoeconomics, Department of MedicineBrigham and Women’s Hospital and Harvard Medical SchoolBostonUSA

Personalised recommendations